Dr. Francis Collins featured our Science paper on the NIH Director’s Blog. The study, led by Gregory Ippolito and Jason Lavinder analyzed the complete repertoire of antibodies against the spike protein from four people soon after their recoveries from mild COVID-19. The first author of the study is William Voss, a graduate student at UT […]
“Researchers at the University of Texas have developed an antibody test for the coronavirus that they say is more accurate, scalable and affordable than the commercially available tests used to analyze blood samples and determine whether an individual was previously infected with the virus that causes COVID-19. The test also could offer a glimpse into […]
Antibody Test Developed for COVID-19 That is Sensitive, Specific and Scalable
Responding to a need to quickly develop billions of doses of lifesaving COVID-19 vaccines, a scientific team at The University of Texas at Austin has successfully redesigned a key protein from the coronavirus, and the modification could enable much faster and more stable production of vaccines worldwide. The new findings are described in the journal […]
The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, has initiated the Collaborative Influenza Vaccine Innovation Centers (CIVICs) program, a new network of research centers that will work together in a coordinated, multidisciplinary effort to develop more durable, broadly protective and longer-lasting influenza vaccines. NIAID will provide up […]
Our very own Dr. Everett Stone recently competed on the TV show Forged in Fire on the History Channel. Congratulations Dr. Stone! The full episode can be viewed here: https://www.history.com/shows/forged-in-fire/season-6/episode-30 photo credit: Marsha Miller Dr. Stone was recently featured in the Texas Scientist Magazine. https://cns.utexas.edu/news/the-tool-maker-the-double-life-of-everett-stone
In our most recent paper, we show that administration of a pharmacologically optimized enzyme (PEGylated kynureninase; hereafter referred to as PEG-KYNase) that degrades Kyn into immunologically inert, nontoxic and readily cleared metabolites inhibits tumor growth. Enzyme treatment was associated with a marked increase in the tumor infiltration and proliferation of polyfunctional CD8+ lymphocytes. We show that PEG-KYNase […]
